Probiotic Saccharomyces cerevisiae strains as biotherapeutic tools: is there room for improvement?
Mariana L. Palma(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Bruno Douradinha(Ri.MED), Daniel Zamith‐Miranda(Universidade Federal do Rio de Janeiro), Flaviano S. Martins(Universidade Federal de Minas Gerais), Ernesto T. A. Marques(Clínica Girona), Mónica Montero-Lomelı́(Universidade Federal do Rio de Janeiro), Fernando A. Bozza(D’Or Institute for Research and Education), Leonardo Nimrichter(Universidade Federal do Rio de Janeiro)
Cited by 111
Related Papers
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19
|Blood|2020|776
Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis
|Critical Care|2007|744
Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data
|The Lancet Respiratory Medicine|2021|527
A Central Role for Free Heme in the Pathogenesis of Severe Sepsis
|Science Translational Medicine|2010|492